Science AI Journal
Medicine · Research topic

Open research questions in Inflammatory Myopathies and Dermatomyositis

45 unresolved questions extracted from the limitations and future-work sections of 162 Inflammatory Myopathies and Dermatomyositis papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • The pathogenicity of the FHL1 c.401A>C (p.Gln134Pro) variant remains unproven. Further studies are necessary to confirm the relationship between the variant and RBM.

    Novel FHL1 Mutation Associated With Reducing Body Myopathy · 2026 · DOI

  • Early diagnosis can be challenging due to limited initial laboratory abnormalities. Delayed treatment can lead to severe complications. The disease can involve multiple systems, making management challenging.

    Dermatomyositis With Necrotizing Vasculitis, Pulmonary Arterial Hypertension, and Extensive Calcinosis Following Delayed Diagnosis · 2026 · DOI

  • The treatment of PAH in DM is challenging due to the limited understanding of the condition. The current treatment options for PAH in DM are limited, and new approaches are needed. The patient's condition was complicated by the presence of refractory cutaneous ulcers and PAH.

    Improvement of Refractory Cutaneous Ulcers and Pulmonary Arterial Hypertension Following Rituximab and Mycophenolate Mofetil Therapy in Anti-melanoma Differentiation-Associated Gene 5 (Anti-MDA5) Antibody-Positive Dermatomyositis · 2026 · DOI

  • The diagnosis of dermatomiositis por anti-MDA5 can be challenging due to its rarity and nonspecific clinical features. The treatment of hepatic involvement in these patients can be difficult due to the lack of effective therapies.

    Esteatosis hepática en la presentación inicial de dos pacientes con dermatomiositis por anti-MDA5 · 2026 · DOI

  • The patient had a complex medical history, including type 2 diabetes, hypertension, dyslipidemia, lacunar stroke, and knee osteoarthritis - The patient had no history of malignancy, autoimmune disease, or smoking - The patient had received the SARS-CoV-2 vaccine several times, but the exact number was unknown

    New-onset Anti-melanoma Differentiation-associated Gene 5 Antibody Positive Clinically Amyopathic Dermatomyositis Following COVID-19 · 2026 · DOI

  • Diagnostic uncertainty due to uncommon presentation. Potential for unnecessary surgical intervention. Need for increased awareness and recognition of musculoskeletal complications.

    Acute Necrotizing Pancreatitis Presenting With Extensive Unilateral Lower Limb Myositis, Fasciitis, and Sterile Reactive Knee Synovitis: A Rare Extra-pancreatic Manifestation · 2026 · DOI

  • Larger multi-center studies are needed to validate the metabolic responder classification criteria and determine predictors of treatment response across diverse IBM populations.

    Modifying muscle metabolic dysregulation in inclusion body myositis with pioglitazone: a single-arm trial · 2026 · DOI

  • The diagnostic utility of nailfold capillaroscopy in juvenile dermatomyositis remains insufficiently defined. Longitudinal outcomes beyond 16 years were previously undocumented.

    Use of nailfold capillaroscopy for evaluation of disease activity in juvenile dermatomyositis: Results of a two-center retrospective study · 2026 · DOI

  • Variable availability of IVIG. High costs of IVIG. Need for new treatments with better outcomes.

    A Phase 3 Trial of Brepocitinib in Dermatomyositis · 2026 · DOI

  • There is a need for new treatments for dermatomyositis with better outcomes. Current treatment often has disappointing outcomes. This paper aims to address this gap by testing a new potential treatment, brepocitinib.

    A Phase 3 Trial of Brepocitinib in Dermatomyositis · 2026 · DOI

  • The first deltoid biopsy was insufficient to establish a diagnosis, likely due to the focal and asymmetric histopathological involvement typical of RBM [5,6].

    Novel FHL1 Mutation Associated With Reducing Body Myopathy · 2026 · DOI

  • The case report lacks long-term follow-up to determine the effect of anesthetic management on disease progression. The study has a small sample size, with only one patient. The study does not provide a control group for comparison.

    Cesarean delivery in a patient with inclusion body myositis: is general anesthesia safe? A case report · 2026 · DOI

  • There is a lack of studies on the use of general anesthesia in IBM patients undergoing cesarean delivery. There is a need for more research on the safety and feasibility of general anesthesia in IBM patients.

    Cesarean delivery in a patient with inclusion body myositis: is general anesthesia safe? A case report · 2026 · DOI

  • The diagnosis of dermatomyositis can be challenging when classic cutaneous features are absent. Overlap phenotypes, such as PM/Scl-positive overlap myositis, are not well understood and can delay recognition.

    Rash-Negative Dermatomyositis-Spectrum Overlap Myositis With PM/Scl Positivity Presenting With Progressive Pharyngeal Dysphagia · 2026 · DOI

  • Further studies are needed to investigate the mechanisms underlying the association between anti-Ro52 antibodies and interstitial lung disease. Future research should examine the potential of anti-Ro52 antibodies as a biomarker for identifying patients with idiopathic inflammatory myopathies who are at risk of developing interstitial lung disease.

    Antibodies against Ro52 in idiopathic inflammatory myopathies are associated with objective sicca symptoms · 2026 · DOI

  • The association between anti-Ro52 antibodies and objective sicca symptoms in patients with idiopathic inflammatory myopathies is not well understood. The clinical phenotype of idiopathic inflammatory myopathies is not fully characterized.

    Antibodies against Ro52 in idiopathic inflammatory myopathies are associated with objective sicca symptoms · 2026 · DOI

  • The study is limited to a single tertiary neuromuscular center. The study does not provide a comprehensive review of the literature. The study does not discuss the cost-effectiveness of muscle biopsy.

    Muscle biopsy in genomic era: real-world diagnostic and clinical implications over 10 years · 2026 · DOI

  • The study is limited to a single case report, which may not be representative of all MRH cases. The treatment of the patient's MRH was not effective in improving symptoms, despite the use of surgery and chemotherapy for the associated bladder cancer.

    Malignancy-associated Multicentric Reticulohistocytosis Mimicking Dermatomyositis-like Features, with a Significant Ultrasound Finding · 2026 · DOI

  • The diagnosis of MRH can be challenging due to similarities with autoimmune diseases. The treatment of MRH is not well established, and the use of surgery and chemotherapy for associated malignancies may not always be effective.

    Malignancy-associated Multicentric Reticulohistocytosis Mimicking Dermatomyositis-like Features, with a Significant Ultrasound Finding · 2026 · DOI

  • There is a need for early recognition and treatment of anti-MDA5 dermatomyositis. The disease has a poor prognosis and requires aggressive management.

    Anti-MDA5 Dermatomyositis with RP-ILD and CMV Reactivation: A Case Report · 2026 · DOI

  • Future research should investigate the mechanisms by which myositis-specific autoantibodies contribute to the development of cancer in dermatomyositis patients. Studies should explore the potential of myositis-specific autoantibodies as biomarkers for malignancy risk in dermatomyositis patients.

    Malignancy Risk and Myositis-Specific Autoantibodies in Dermatomyositis: A Comprehensive Review · 2026 · DOI

  • Further studies are needed to fully understand the role of GZMB+CD4+ CTLs in the pathogenesis of DM and ASS. The clinical utility of GZMB+CD4+ CTLs as a biomarker for DM and ASS should be further evaluated. The potential of targeting GZMB+CD4+ CTLs as a therapeutic strategy for DM and ASS should be explored.

    Dermatomyositis and antisynthetase syndrome disease activity is associated with the expansion of peripheral GZMB+CD4+ cytotoxic T cells · 2026 · DOI

  • The role of CD4+ cytotoxic T lymphocytes in the pathogenesis of DM and ASS is insufficiently defined. There is a need for innovative diagnostic and therapeutic approaches for DM and ASS. The current understanding of the immune responses involved in DM and ASS is incomplete.

    Dermatomyositis and antisynthetase syndrome disease activity is associated with the expansion of peripheral GZMB+CD4+ cytotoxic T cells · 2026 · DOI

  • The study is limited to a single case report, and further studies are needed to confirm the efficacy of the treatment approach. The patient's anti-MDA5 antibody levels were not serially assessed during the active phase, making it difficult to evaluate the relationship between changes in antibody levels and clinical improvement.

    Improvement of Refractory Cutaneous Ulcers and Pulmonary Arterial Hypertension Following Rituximab and Mycophenolate Mofetil Therapy in Anti-melanoma Differentiation-Associated Gene 5 (Anti-MDA5) Antibody-Positive Dermatomyositis · 2026 · DOI

  • The pathophysiology of hepatic involvement in dermatomiositis por anti-MDA5 is not fully understood. There is a need for further studies to investigate the relationship between hepatic involvement and patient outcomes.

    Esteatosis hepática en la presentación inicial de dos pacientes con dermatomiositis por anti-MDA5 · 2026 · DOI

Most-cited papers in Inflammatory Myopathies and Dermatomyositis

Most recent work

Find a gap in your own Inflammatory Myopathies and Dermatomyositis sub-topic

This page shows what the Inflammatory Myopathies and Dermatomyositis literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Substance Abuse Treatment and Outcomes
1,213 open questions
Artificial Intelligence in Healthcare and Education
1,153 open questions
Physical Activity and Health
718 open questions
Dementia and Cognitive Impairment Research
565 open questions
Attention Deficit Hyperactivity Disorder
544 open questions
Smoking Behavior and Cessation
532 open questions
Innovations in Medical Education
480 open questions
HIV/AIDS Research and Interventions
472 open questions
45 open questions have been extracted from the limitations and future-work passages of 162 Inflammatory Myopathies and Dermatomyositis papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.